speb/financial-data huggingface dataset:
MRNA balance_sheet (quarterly, 2025-12-31) — Accrued Interest Receivable: 42000000.00
MRNA balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -737000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -737000000.00
MRNA balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1382000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1382000000.00
MRNA balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -184000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -184000000.00
MRNA cash_flow (annual, 2025-12-31) — Amortization Of Securities: -67000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Amortization Of Securities: -13000000.00
MRNA balance_sheet (annual, 2025-12-31) — Available For Sale Securities: 2336000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Available For Sale Securities: 2336000000.00
MRNA income_statement (annual, 2025-12-31) — Basic Average Shares: 389000000.00
MRNA income_statement (quarterly, 2025-12-31) — Basic Average Shares: 392000000.00
MRNA income_statement (annual, 2025-12-31) — Basic EPS: -7.26
MRNA income_statement (quarterly, 2025-12-31) — Basic EPS: -2.11
MRNA cash_flow (annual, 2025-12-31) — Beginning Cash Position: 1929000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 1134000000.00
MRNA balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 1183000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 1183000000.00
MRNA cash_flow (annual, 2025-12-31) — Capital Expenditure: -202000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -39000000.00
MRNA balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 715000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 715000000.00
MRNA balance_sheet (annual, 2025-12-31) — Capital Stock: 0.00
MRNA balance_sheet (quarterly, 2025-12-31) — Capital Stock: 0.00
MRNA balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 2595000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 2595000000.00
MRNA balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 5799000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 5799000000.00
MRNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 593000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 581000000.00
MRNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 1946000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -48000000.00
MRNA cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -1873000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 930000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Account Payable: -92000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 22000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Accrued Expense: -2000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 194000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Inventory: -34000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Inventory: 179000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Other Current Assets: 38000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: 10000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -27000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: 125000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Other Working Capital: 41000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -67000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Payable: -92000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Payable: 22000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -94000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 216000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 153000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 237000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Receivables: 156000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Receivables: 859000000.00
MRNA cash_flow (annual, 2025-12-31) — Change In Working Capital: 233000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 1559000000.00
MRNA cash_flow (annual, 2025-12-31) — Changes In Account Receivables: 156000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: 859000000.00
MRNA cash_flow (annual, 2025-12-31) — Changes In Cash: 666000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Changes In Cash: 1463000000.00
MRNA balance_sheet (annual, 2025-12-31) — Common Stock: 0.00
MRNA balance_sheet (quarterly, 2025-12-31) — Common Stock: 0.00
MRNA balance_sheet (annual, 2025-12-31) — Common Stock Equity: 8650000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 8650000000.00
MRNA cash_flow (annual, 2025-12-31) — Common Stock Issuance: 35000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 16000000.00
MRNA balance_sheet (annual, 2025-12-31) — Construction In Progress: 298000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 298000000.00
MRNA income_statement (annual, 2025-12-31) — Cost Of Revenue: 868000000.00
MRNA income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 452000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 457000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 457000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Assets: 6544000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Assets: 6544000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 42000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 42000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 42000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 42000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 99000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 99000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 99000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 99000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Liabilities: 1987000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 1987000000.00
MRNA balance_sheet (annual, 2025-12-31) — Current Provisions: 509000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Current Provisions: 509000000.00
MRNA cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 215000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 67000000.00
MRNA cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 215000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 67000000.00
MRNA income_statement (annual, 2025-12-31) — Diluted Average Shares: 389000000.00
MRNA income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 392000000.00
MRNA income_statement (annual, 2025-12-31) — Diluted EPS: -7.26
MRNA income_statement (quarterly, 2025-12-31) — Diluted EPS: -2.11
MRNA income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -2822000000.00
MRNA income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -826000000.00
MRNA income_statement (annual, 2025-12-31) — EBIT: -2758000000.00
MRNA income_statement (quarterly, 2025-12-31) — EBIT: -791000000.00
MRNA income_statement (annual, 2025-12-31) — EBITDA: -2543000000.00
MRNA income_statement (quarterly, 2025-12-31) — EBITDA: -724000000.00
MRNA cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: 8000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: 3000000.00
MRNA cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 2000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 0.00
MRNA cash_flow (annual, 2025-12-31) — End Cash Position: 2597000000.00
MRNA cash_flow (quarterly, 2025-12-31) — End Cash Position: 2597000000.00
MRNA cash_flow (annual, 2025-12-31) — Financing Cash Flow: 593000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 581000000.00
MRNA balance_sheet (annual, 2025-12-31) — Finished Goods: 33000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Finished Goods: 33000000.00
MRNA cash_flow (annual, 2025-12-31) — Free Cash Flow: -2075000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 891000000.00
MRNA income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -5000000.00
MRNA income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -2000000.00
MRNA balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 45000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 45000000.00
MRNA balance_sheet (annual, 2025-12-31) — Goodwill: 52000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Goodwill: 52000000.00
MRNA balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 97000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 97000000.00
MRNA balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 368000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 368000000.00
MRNA balance_sheet (annual, 2025-12-31) — Gross PPE: 3590000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Gross PPE: 3590000000.00
MRNA income_statement (annual, 2025-12-31) — Gross Profit: 1054000000.00
MRNA income_statement (quarterly, 2025-12-31) — Gross Profit: 224000000.00
MRNA cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 26000000.00
MRNA income_statement (annual, 2025-12-31) — Interest Expense: 10000000.00
MRNA income_statement (quarterly, 2025-12-31) — Interest Expense: 8000000.00
MRNA income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 10000000.00
MRNA income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 8000000.00
MRNA income_statement (annual, 2025-12-31) — Interest Income: 314000000.00
MRNA income_statement (quarterly, 2025-12-31) — Interest Income: 70000000.00
MRNA income_statement (annual, 2025-12-31) — Interest Income Non Operating: 314000000.00
MRNA income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 70000000.00
MRNA cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 10000000.00
MRNA balance_sheet (annual, 2025-12-31) — Inventory: 153000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Inventory: 153000000.00
MRNA balance_sheet (annual, 2025-12-31) — Invested Capital: 9240000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Invested Capital: 9240000000.00
MRNA cash_flow (annual, 2025-12-31) — Investing Cash Flow: 1946000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -48000000.00
MRNA balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 2336000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Investmentin Financial Assets: 2336000000.00
MRNA balance_sheet (annual, 2025-12-31) — Investments And Advances: 2342000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 2342000000.00
MRNA cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 35000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 16000000.00
MRNA cash_flow (annual, 2025-12-31) — Issuance Of Debt: 600000000.00
MRNA balance_sheet (annual, 2025-12-31) — Land And Improvements: 78000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 78000000.00
MRNA balance_sheet (annual, 2025-12-31) — Leases: 403000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Leases: 403000000.00
MRNA balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 673000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 673000000.00
MRNA balance_sheet (annual, 2025-12-31) — Long Term Debt: 590000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 590000000.00
MRNA balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1263000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1263000000.00
MRNA cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 600000000.00
MRNA cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -22000000.00
MRNA balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 6000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 6000000.00
MRNA balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 235000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 235000000.00
MRNA cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
MRNA cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 35000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 16000000.00
MRNA income_statement (annual, 2025-12-31) — Net Income: -2822000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Income: -826000000.00
MRNA income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -2822000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -826000000.00
MRNA income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -2822000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -826000000.00
MRNA income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -2822000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -826000000.00
MRNA income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -2822000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -826000000.00
MRNA cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -2822000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -826000000.00
MRNA income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -2822000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -826000000.00
MRNA cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -10000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
MRNA income_statement (annual, 2025-12-31) — Net Interest Income: 304000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Interest Income: 62000000.00
MRNA cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 2148000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -9000000.00
MRNA cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 560000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 566000000.00
MRNA cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 560000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: 566000000.00
MRNA income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 304000000.00
MRNA income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 62000000.00
MRNA cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -2000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -1000000.00
MRNA balance_sheet (annual, 2025-12-31) — Net PPE: 2853000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Net PPE: 2853000000.00
MRNA cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -192000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -39000000.00
MRNA balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 8553000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 8553000000.00
MRNA balance_sheet (annual, 2025-12-31) — Non Current Accounts Receivable: 161000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Non Current Accounts Receivable: 161000000.00
MRNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 81000000.00
MRNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 153000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 153000000.00
MRNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 153000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 153000000.00
MRNA balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 81000000.00
MRNA balance_sheet (annual, 2025-12-31) — Non Current Prepaid Assets: 100000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Non Current Prepaid Assets: 100000000.00
MRNA income_statement (annual, 2025-12-31) — Normalized EBITDA: -2538000000.00
MRNA income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -722000000.00
MRNA income_statement (annual, 2025-12-31) — Normalized Income: -2818050000.00
MRNA income_statement (quarterly, 2025-12-31) — Normalized Income: -824420000.00
MRNA cash_flow (annual, 2025-12-31) — Operating Cash Flow: -1873000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 930000000.00
MRNA cash_flow (annual, 2025-12-31) — Operating Gains Losses: 8000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 3000000.00
MRNA income_statement (annual, 2025-12-31) — Operating Income: -3074000000.00
MRNA income_statement (quarterly, 2025-12-31) — Operating Income: -857000000.00
MRNA income_statement (annual, 2025-12-31) — Operating Revenue: 3304000000.00
MRNA income_statement (quarterly, 2025-12-31) — Operating Revenue: 1053000000.00
MRNA balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 394000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 394000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Current Assets: 45000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 45000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 143000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 143000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 45000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 45000000.00
MRNA income_statement (annual, 2025-12-31) — Other Income Expense: 2000000.00
MRNA income_statement (quarterly, 2025-12-31) — Other Income Expense: -4000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 45000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 45000000.00
MRNA cash_flow (annual, 2025-12-31) — Other Non Cash Items: 77000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 27000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 160000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 160000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 36000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 36000000.00
MRNA income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 7000000.00
MRNA income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -2000000.00
MRNA income_statement (annual, 2025-12-31) — Other Operating Expenses: -22000000.00
MRNA income_statement (quarterly, 2025-12-31) — Other Operating Expenses: -2000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Properties: 1393000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Properties: 1393000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Receivables: 13000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Receivables: 13000000.00
MRNA balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 3204000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 3204000000.00
MRNA balance_sheet (annual, 2025-12-31) — Payables: 317000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Payables: 317000000.00
MRNA balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 774000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 774000000.00
MRNA balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 420000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 420000000.00
MRNA balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
MRNA balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
MRNA balance_sheet (annual, 2025-12-31) — Prepaid Assets: 263000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 263000000.00
MRNA income_statement (annual, 2025-12-31) — Pretax Income: -2768000000.00
MRNA income_statement (quarterly, 2025-12-31) — Pretax Income: -799000000.00
MRNA balance_sheet (annual, 2025-12-31) — Properties: 0.00
MRNA balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
MRNA cash_flow (annual, 2025-12-31) — Purchase Of Business: 0.00
MRNA cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -10000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: 0.00
MRNA cash_flow (annual, 2025-12-31) — Purchase Of Investment: -5768000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -1547000000.00
MRNA cash_flow (annual, 2025-12-31) — Purchase Of PPE: -192000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -39000000.00
MRNA balance_sheet (annual, 2025-12-31) — Raw Materials: 91000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Raw Materials: 91000000.00
MRNA balance_sheet (annual, 2025-12-31) — Receivables: 284000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Receivables: 284000000.00
MRNA income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 868000000.00
MRNA income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 452000000.00
MRNA income_statement (annual, 2025-12-31) — Reconciled Depreciation: 215000000.00
MRNA income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 67000000.00
MRNA cash_flow (annual, 2025-12-31) — Repayment Of Debt: -22000000.00
MRNA income_statement (annual, 2025-12-31) — Research And Development: 3132000000.00
MRNA income_statement (quarterly, 2025-12-31) — Research And Development: 775000000.00
MRNA balance_sheet (annual, 2025-12-31) — Retained Earnings: 7223000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Retained Earnings: 7223000000.00
MRNA cash_flow (annual, 2025-12-31) — Sale Of Investment: 7916000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 1538000000.00
MRNA income_statement (annual, 2025-12-31) — Selling General And Administration: 1018000000.00
MRNA income_statement (quarterly, 2025-12-31) — Selling General And Administration: 308000000.00
MRNA balance_sheet (annual, 2025-12-31) — Share Issued: 394000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Share Issued: 394000000.00
MRNA cash_flow (annual, 2025-12-31) — Stock Based Compensation: 483000000.00
MRNA cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 113000000.00
MRNA balance_sheet (annual, 2025-12-31) — Stockholders Equity: 8650000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 8650000000.00
MRNA balance_sheet (annual, 2025-12-31) — Tangible Book Value: 8553000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 8553000000.00
MRNA income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -1050000.00
MRNA income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -420000.00
MRNA income_statement (annual, 2025-12-31) — Tax Provision: 54000000.00
MRNA income_statement (quarterly, 2025-12-31) — Tax Provision: 27000000.00
MRNA income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.21
MRNA income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
MRNA balance_sheet (annual, 2025-12-31) — Taxes Receivable: 45000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 45000000.00
MRNA balance_sheet (annual, 2025-12-31) — Total Assets: 12338000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Total Assets: 12338000000.00
MRNA balance_sheet (annual, 2025-12-31) — Total Capitalization: 9240000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 9240000000.00
MRNA balance_sheet (annual, 2025-12-31) — Total Debt: 1305000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Total Debt: 1305000000.00
MRNA balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 8650000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 8650000000.00
MRNA income_statement (annual, 2025-12-31) — Total Expenses: 4996000000.00
MRNA income_statement (quarterly, 2025-12-31) — Total Expenses: 1533000000.00
MRNA balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 3688000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 3688000000.00
MRNA balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 5794000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 5794000000.00
MRNA balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1701000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1701000000.00
MRNA income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -3074000000.00
MRNA income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -857000000.00
MRNA income_statement (annual, 2025-12-31) — Total Unusual Items: -5000000.00
MRNA income_statement (quarterly, 2025-12-31) — Total Unusual Items: -2000000.00
MRNA income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -5000000.00
MRNA income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -2000000.00
MRNA balance_sheet (annual, 2025-12-31) — Tradeand Other Payables Non Current: 249000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 249000000.00
MRNA balance_sheet (annual, 2025-12-31) — Work In Process: 29000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Work In Process: 29000000.00
MRNA balance_sheet (annual, 2025-12-31) — Working Capital: 4557000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Working Capital: 4557000000.00
MRNA income_statement (quarterly, 2026-03-31) — +Operating Expense: 822000000.00
MRNA income_statement (quarterly, 2026-03-31) — +Total Revenue: 389000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 161000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 71000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Accrued Interest Receivable: 39000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -794000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1503000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -132000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Amortization Of Securities: -11000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 2251000000.00
MRNA income_statement (quarterly, 2026-03-31) — Basic Average Shares: 395000000.00
MRNA income_statement (quarterly, 2026-03-31) — Basic EPS: -3.40
MRNA cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 2597000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 1216000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -62000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 708000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Capital Stock: 0.00
MRNA balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 1908000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 5205000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 17000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -76000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -630000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -120000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: 464000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Inventory: 6000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: 11000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: 19000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: 5000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Payable: -120000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 344000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 54000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Receivables: 114000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 553000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 114000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Changes In Cash: -689000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Common Stock: 0.00
MRNA balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 7408000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 19000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 268000000.00
MRNA income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 955000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 1334000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Assets: 5770000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 50000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 50000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 102000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 102000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 2395000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Current Provisions: 470000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 59000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 59000000.00
MRNA income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 395000000.00
MRNA income_statement (quarterly, 2026-03-31) — Diluted EPS: -3.40
MRNA income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -1343000000.00
MRNA income_statement (quarterly, 2026-03-31) — EBIT: -1317000000.00
MRNA income_statement (quarterly, 2026-03-31) — EBITDA: -1258000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: 2000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 1000000.00
MRNA cash_flow (quarterly, 2026-03-31) — End Cash Position: 1909000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 17000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Finished Goods: 14000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -692000000.00
MRNA income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -1000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 25000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Goodwill: 52000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 168000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 203000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Gross PPE: 3586000000.00
MRNA income_statement (quarterly, 2026-03-31) — Gross Profit: -566000000.00
MRNA income_statement (quarterly, 2026-03-31) — Interest Expense: 17000000.00
MRNA income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 17000000.00
MRNA income_statement (quarterly, 2026-03-31) — Interest Income: 72000000.00
MRNA income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 72000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Inventory: 146000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Invested Capital: 7998000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -76000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 2251000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 2251000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 19000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 77000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Leases: 408000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 658000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 590000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1248000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 236000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 19000000.00
MRNA income_statement (quarterly, 2026-03-31) — Net Income: -1343000000.00
MRNA income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -1343000000.00
MRNA income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -1343000000.00
MRNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -1343000000.00
MRNA income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -1343000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -1343000000.00
MRNA income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -1343000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: 0.00
MRNA income_statement (quarterly, 2026-03-31) — Net Interest Income: 55000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -14000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 0.00
MRNA cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 0.00
MRNA income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 55000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -2000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Net PPE: 2792000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -62000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 7240000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Non Current Accounts Receivable: 161000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 82000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 154000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 154000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 82000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 97000000.00
MRNA income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -1257000000.00
MRNA income_statement (quarterly, 2026-03-31) — Normalized Income: -1342400000.00
MRNA cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -630000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 2000000.00
MRNA income_statement (quarterly, 2026-03-31) — Operating Income: -1388000000.00
MRNA income_statement (quarterly, 2026-03-31) — Operating Revenue: 350000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 396586862.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 51000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 170000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 25000000.00
MRNA income_statement (quarterly, 2026-03-31) — Other Income Expense: -1000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 116000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 6000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 167000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 30000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Properties: 1381000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Receivables: 8000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 3297000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Payables: 161000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 1495000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 108000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
MRNA balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 186000000.00
MRNA income_statement (quarterly, 2026-03-31) — Pretax Income: -1334000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
MRNA cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: 0.00
MRNA cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: -1348000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -62000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Raw Materials: 94000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Receivables: 182000000.00
MRNA income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 955000000.00
MRNA income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 59000000.00
MRNA income_statement (quarterly, 2026-03-31) — Research And Development: 649000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 5880000000.00
MRNA cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 1334000000.00
MRNA income_statement (quarterly, 2026-03-31) — Selling General And Administration: 173000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Share Issued: 396586862.00
MRNA cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 104000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 7408000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 7240000000.00
MRNA income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -400000.00
MRNA income_statement (quarterly, 2026-03-31) — Tax Provision: 9000000.00
MRNA income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
MRNA balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 64000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Total Assets: 11488000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 7998000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Total Debt: 1298000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 7408000000.00
MRNA income_statement (quarterly, 2026-03-31) — Total Expenses: 1777000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 4080000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 5718000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 1685000000.00
MRNA income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -1388000000.00
MRNA income_statement (quarterly, 2026-03-31) — Total Unusual Items: -1000000.00
MRNA income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -1000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 253000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Work In Process: 38000000.00
MRNA balance_sheet (quarterly, 2026-03-31) — Working Capital: 3375000000.00
MRNO balance_sheet (annual, 2021-12-31) — Duefrom Related Parties Current: 2101506.00
MRNO balance_sheet (annual, 2021-12-31) — Financial Assets: 0.00
MRNO balance_sheet (annual, 2021-12-31) — Loans Receivable: 2101506.00
MRNO cash_flow (annual, 2021-12-31) — Net Other Financing Charges: 5806279.00
MRNO balance_sheet (annual, 2021-12-31) — Ordinary Shares Number: 79242873.00
MRNO balance_sheet (annual, 2021-12-31) — Other Current Liabilities: 35317440.00
MRNO income_statement (annual, 2021-12-31) — Research And Development: 0.00
MRNO balance_sheet (annual, 2021-12-31) — Restricted Cash: 44895098.00
MRNO balance_sheet (annual, 2021-12-31) — Share Issued: 79242873.00
MRNO income_statement (annual, 2022-12-31) — +Operating Expense: 194181203.00
MRNO income_statement (annual, 2022-12-31) — +Total Revenue: 6431022.00
MRNO balance_sheet (annual, 2022-12-31) — Accounts Payable: 124585497.00
MRNO balance_sheet (annual, 2022-12-31) — Accounts Receivable: 0.00
MRNO balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -14781820.00
MRNO income_statement (annual, 2022-12-31) — Basic Average Shares: 79242873.00
MRNO income_statement (annual, 2022-12-31) — Basic EPS: 3.08
MRNO cash_flow (annual, 2022-12-31) — Beginning Cash Position: 183434795.00
MRNO balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 0.00
MRNO cash_flow (annual, 2022-12-31) — Capital Expenditure: -1523373463.00
MRNO balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 624189.00
MRNO balance_sheet (annual, 2022-12-31) — Capital Stock: 902611512.00
MRNO balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 176976543.00
MRNO balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 215699349.00
MRNO cash_flow (annual, 2022-12-31) — Cash Dividends Paid: 0.00
MRNO balance_sheet (annual, 2022-12-31) — Cash Equivalents: 176542100.00
MRNO balance_sheet (annual, 2022-12-31) — Cash Financial: 434443.00
MRNO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 1770353133.00
MRNO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -1437521734.00
MRNO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -275511389.00
MRNO cash_flow (annual, 2022-12-31) — Change In Account Payable: 25276683.00
MRNO cash_flow (annual, 2022-12-31) — Change In Inventory: -1912518.00
MRNO cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 73362.00
MRNO cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: 0.00
MRNO cash_flow (annual, 2022-12-31) — Change In Other Working Capital: -18034581.00
MRNO cash_flow (annual, 2022-12-31) — Change In Payable: 25276683.00
MRNO cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 25276683.00
MRNO cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 2065240.00
MRNO cash_flow (annual, 2022-12-31) — Change In Receivables: -69608538.00
MRNO cash_flow (annual, 2022-12-31) — Change In Working Capital: -62140352.00
MRNO cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 0.00
MRNO cash_flow (annual, 2022-12-31) — Changes In Cash: 57320010.00
MRNO balance_sheet (annual, 2022-12-31) — Common Stock: 902611512.00
MRNO balance_sheet (annual, 2022-12-31) — Common Stock Equity: 8399334985.00
MRNO cash_flow (annual, 2022-12-31) — Common Stock Issuance: 428378.00
MRNO cash_flow (annual, 2022-12-31) — Common Stock Payments: -298773702.00
MRNO balance_sheet (annual, 2022-12-31) — Construction In Progress: 9083995555.00
MRNO income_statement (annual, 2022-12-31) — Cost Of Revenue: 28614555.00
MRNO balance_sheet (annual, 2022-12-31) — Current Assets: 519743718.00
MRNO balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 387617.00
MRNO balance_sheet (annual, 2022-12-31) — Current Debt: 3795787027.00
MRNO balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 3796174644.00
MRNO balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 0.00
MRNO balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 0.00
MRNO balance_sheet (annual, 2022-12-31) — Current Liabilities: 4069428200.00
MRNO cash_flow (annual, 2022-12-31) — Depreciation: 1808883.00
MRNO cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 1808883.00
MRNO income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 1808833.00
MRNO cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 1808883.00
MRNO income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 1808833.00
MRNO balance_sheet (annual, 2022-12-31) — Derivative Product Liabilities: 0.00
MRNO income_statement (annual, 2022-12-31) — Diluted Average Shares: 79242873.00
MRNO income_statement (annual, 2022-12-31) — Diluted EPS: 3.08
MRNO income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 244377300.00
MRNO balance_sheet (annual, 2022-12-31) — Duefrom Related Parties Current: 0.00
MRNO balance_sheet (annual, 2022-12-31) — Dueto Related Parties Current: 68343487.00
MRNO balance_sheet (annual, 2022-12-31) — Dueto Related Parties Non Current: 206145860.00
MRNO income_statement (annual, 2022-12-31) — EBIT: 561572390.00
MRNO income_statement (annual, 2022-12-31) — EBITDA: 563381273.00
MRNO balance_sheet (annual, 2022-12-31) — Employee Benefits: 6654318.00
MRNO cash_flow (annual, 2022-12-31) — End Cash Position: 240754805.00
MRNO balance_sheet (annual, 2022-12-31) — Financial Assets: 192791990.00
MRNO cash_flow (annual, 2022-12-31) — Financing Cash Flow: 1770353133.00
MRNO cash_flow (annual, 2022-12-31) — Free Cash Flow: -1798884852.00
MRNO cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -498829796.00
MRNO cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 0.00
MRNO income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: 203909.00
MRNO income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 775577666.00
MRNO balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 8735561229.00
MRNO income_statement (annual, 2022-12-31) — General And Administrative Expense: 110306191.00
MRNO balance_sheet (annual, 2022-12-31) — Gross PPE: 16897856688.00
MRNO income_statement (annual, 2022-12-31) — Gross Profit: -22183533.00
MRNO balance_sheet (annual, 2022-12-31) — Income Tax Payable: 18744910.00
MRNO income_statement (annual, 2022-12-31) — Insurance And Claims: 3891189.00
MRNO income_statement (annual, 2022-12-31) — Interest Expense: 86485683.00
MRNO income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 86485683.00
MRNO income_statement (annual, 2022-12-31) — Interest Income: 555638.00
MRNO income_statement (annual, 2022-12-31) — Interest Income Non Operating: 555638.00
MRNO cash_flow (annual, 2022-12-31) — Interest Paid Cff: -45065474.00
MRNO cash_flow (annual, 2022-12-31) — Interest Received Cfi: 555638.00
MRNO balance_sheet (annual, 2022-12-31) — Inventory: 1912518.00
MRNO balance_sheet (annual, 2022-12-31) — Invested Capital: 13962509989.00
MRNO cash_flow (annual, 2022-12-31) — Investing Cash Flow: -1437521734.00
MRNO balance_sheet (annual, 2022-12-31) — Investment Properties: 1187089926.00
MRNO cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 428378.00
MRNO cash_flow (annual, 2022-12-31) — Issuance Of Debt: 2387544787.00
MRNO balance_sheet (annual, 2022-12-31) — Land And Improvements: 7794417256.00
MRNO balance_sheet (annual, 2022-12-31) — Loans Receivable: 0.00
MRNO balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 236572.00